These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8425646)

  • 21. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin.
    Dawood MY; Ramos J; Khan-Dawood FS
    Fertil Steril; 1995 Jun; 63(6):1177-83. PubMed ID: 7750585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo.
    Friedman AJ; Daly M; Juneau-Norcross M; Fine C; Rein MS
    Fertil Steril; 1992 Jul; 58(1):205-8. PubMed ID: 1624009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukopenia induced by leuprolide acetate depot.
    Grau E; Torrecilla T; Real E; Sempere J
    Ann Pharmacother; 1994 Feb; 28(2):283-4. PubMed ID: 8173155
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata.
    Friedman AJ; Harrison-Atlas D; Barbieri RL; Benacerraf B; Gleason R; Schiff I
    Fertil Steril; 1989 Feb; 51(2):251-6. PubMed ID: 2492232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study].
    Schindler AE; Bühler K; Gerhard I; Wiedemann R; Kimmig R; Schüssler B; Kranzfelder D; Mall-Häfeli M; Meinen K; Mancarella D
    Zentralbl Gynakol; 1994; 116(12):679-86. PubMed ID: 7846980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
    Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
    Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroidal 'add-back' therapy in patients treated with GnRH agonists.
    Freundl G; Gödtke K; Gnoth C; Godehardt E; Kienle E
    Gynecol Obstet Invest; 1998; 45 Suppl 1():22-30; discussion 35. PubMed ID: 9628521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women.
    Grigorova M; Sherwin BB; Tulandi T
    Psychoneuroendocrinology; 2006 Sep; 31(8):935-47. PubMed ID: 16831518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
    Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
    Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suspected anaphylaxis to leuprolide acetate depot in two elf owls (Micrathene whitneyi).
    Stringer EM; De Voe RS; Loomis MR
    J Zoo Wildl Med; 2011 Mar; 42(1):166-8. PubMed ID: 22946393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
    Bhatia S; Neely EK; Wilson DM
    Pediatrics; 2002 Feb; 109(2):E30. PubMed ID: 11826240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results.
    Wheeler JM; Knittle JD; Miller JD
    Am J Obstet Gynecol; 1992 Nov; 167(5):1367-71. PubMed ID: 1442992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy.
    Friedman AJ; Rein MS; Harrison-Atlas D; Garfield JM; Doubilet PM
    Fertil Steril; 1989 Nov; 52(5):728-33. PubMed ID: 2509250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group.
    Wheeler JM; Knittle JD; Miller JD
    Am J Obstet Gynecol; 1993 Jul; 169(1):26-33. PubMed ID: 8333471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program.
    Hsieh Y; Tsai H; Chang C; Lo H
    Fertil Steril; 2000 Apr; 73(4):817-20. PubMed ID: 10731546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.